Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for HFpEF with overweight or insulin resistance
ISRCTN74144960Phase 2Active, not recruiting
- Sponsor
- University of Sulaimani
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing Metformin modified-release with Matched placebo (2 arms). Primary endpoint: Left ventricular mass index. Started Aug 2026; status: active, not recruiting.
02
Drugs
metformin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on ISRCTN74144960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN74144960.